In light of our in vivo and in vitro findings, we propose that ovarian cancer patients with KRAS or BRAF mutations be considered for MEK inhibitor (CI-1040) therapy if they recur after conventional platinum and taxane chemotherapy. Here, KRAS is linked to ovarian cancer.